Abdominal Chemotherapy Perfusion Effective on Treatment-resistant, Recurrent OC in Phase 2 Study

Abdominal Chemotherapy Perfusion Effective on Treatment-resistant, Recurrent OC in Phase 2 Study
Localized chemotherapy perfusion in the abdomen showed efficacy in patients with treatment-resistant and recurrent ovarian cancer, according to preliminary results of an ongoing Phase 2 clinical study. A subset of the patients showed complete cancer remission. The study, Hypoxic isolated abdominal perfusion breaks through chemoresistance in recurrent FIGO stage IIIC and IV ovarian Cancer: experience in 143 platinum-refractory and 25 chemonaive ovarian cancer patients,” was presented at the recent 38th Congress of the European Society of Surgical Oncology (ESSO) in Budapest, Hungary. “Increased dose or dose-dense chemotherapy for platinum-refractory ovarian cancer is limited because of increasing toxicity,” Karl R. Aigner, the study’s first author and head of the department of surgical oncology and medical director at German private hospital Medias Klinikum, noted in a press release. An expert in regional chemotherapy, Aigner originally developed isolated liver perfusion and was the first physician worldwide to perform this method using a heart-lung machine. To overcome treatment resistance and toxicity, Aigner and colleagues examined whether increased therapy exposure restricted to the abdomen — an approach called regional chemotherapy – could improve the outcomes of treatment-resistant patients. The chemotherapy was administered t
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *